Demographics (2)
- AGE - Subject age at enrollment (phv00570529.v1.p1)
- SEX - Biological sex (phv00570525.v1.p1)
Disease Events (5)
- DFS_DAYS - Disease-free survival time (phv00570532.v1.p1)
- DFS_EVENT - Disease-free survival event (phv00570531.v1.p1)
- PERCENT_NECROSIS - Tumor percent necrosis after neoadjuvant therapy (phv00570535.v1.p1)
- TUMOR_GRADE - Tumor grade (phv00570533.v1.p1)
- TUMOR_HISTOLOGY - Tumor histology (phv00570534.v1.p1)
Other (12)
- ANALYTE_TYPE - Analyte type (phv00570538.v1.p1)
- ARM - Treatment arm (phv00570530.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00570537.v1.p1)
- CONSENT - Registered consent groups (Data Use Limitations (DUL)) as determined by submitters' Institutional Review Boards (IRB) or equivalent body. (phv00570524.v1.p1)
- IS_TUMOR - Tumor status (phv00570539.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary tumor, metastasis, or transformed cell line (phv00570540.v1.p1)
- SAMPLE_ID - Sample ID (phv00570536.v1.p1)
- SAMPLE_ID - Sample ID (phv00570527.v1.p1)
- SUBJECT_ID - Subject ID (phv00570528.v1.p1)
- SUBJECT_ID - Subject ID (phv00570523.v1.p1)
- SUBJECT_ID - Subject ID (phv00570526.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00570541.v1.p1)